Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 645

1.

Reappraisal of EBV in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and -negative DLBCL with EBV-positive bystander cells.

Ohashi A, Kato S, Okamoto A, Inaguma Y, Satou A, Tsuzuki T, Emi N, Okamoto M, Nakamura S.

Histopathology. 2017 Feb 23. doi: 10.1111/his.13197. [Epub ahead of print]

PMID:
28231401
2.

What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?

Cosnes J.

Dig Dis. 2017;35(1-2):50-55. doi: 10.1159/000449083. Review.

PMID:
28147366
3.

Epstein-Barr virus-positive follicular lymphoma.

Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, Levy R, Verdun RE, Kunkalla K, Natkunam Y, Lossos IS, Vega F, Chapman J.

Mod Pathol. 2016 Dec 16. doi: 10.1038/modpathol.2016.214. [Epub ahead of print]

PMID:
27982024
5.

HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.

Hussain SK, Makgoeng SB, Everly MJ, Goodman MT, Martínez-Maza O, Morton LM, Clarke CA, Lynch CF, Snyder J, Israni A, Kasiske BL, Engels EA.

Transplantation. 2016 Nov;100(11):2453-2460.

PMID:
26636741
6.

[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].

Gui L, He XH, Liu P, Yang JL, Qin Y, Zhou SY, Yang S, Zhang CG, Shi YK.

Zhonghua Xue Ye Xue Za Zhi. 2016 Sep 14;37(9):762-767. doi: 10.3760/cma.j.issn.0253-2727.2016.09.007. Chinese.

PMID:
27719718
7.

Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Morscio J, Tousseyn T.

World J Transplant. 2016 Sep 24;6(3):505-16. doi: 10.5500/wjt.v6.i3.505. Review.

8.

A Solid Mass in the Chest Wall: An Unusual Presentation of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Recipient.

Alagoz S, Yalin SF, Gulcicek S, Ozgur N, Altiparmak MR, Seyahi N.

Prog Transplant. 2016 Aug 22. pii: 1526924816663517. [Epub ahead of print]

PMID:
27555070
9.

Lymphoproliferative Disease, X-Linked.

Zhang K, Wakefield E, Marsh R.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2004 Feb 27 [updated 2016 Jun 30].

10.

A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.

Soriano-López DP, Alcántar-Fierros JM, Hernández-Plata JA, González-Jorge AL, Velázquez-Ramos S, Flores-Hernández MA, Fuentes V, Castañeda P, Nieto J, Sánchez JL, López B, Valencia-Mayoral P, Varela-Fascinetto G.

Transplant Proc. 2016 Mar;48(2):654-7. doi: 10.1016/j.transproceed.2016.02.031.

PMID:
27110023
11.

EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.

Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM.

Am J Hematol. 2016 May;91(5):529-37. doi: 10.1002/ajh.24370. Review.

PMID:
27093913
12.

Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics.

Loghavi S.

Methods Mol Biol. 2016;1392:51-61. doi: 10.1007/978-1-4939-3360-0_6.

PMID:
26843046
13.

Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.

Battle-Lopez A, Gonzalez de Villambrosia S, Nuñez J, Cagigal ML, Montes-Moreno S, Conde E, Piris MA.

Expert Rev Anticancer Ther. 2016;16(4):411-21. doi: 10.1586/14737140.2016.1149065. Review.

PMID:
26838128
14.

Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.

Deng R, Yi H, Liu YL, Fan FY, Fu LI, Li YC, Li GS, Lai SH, Miao XJ, Shuai YR, He GC, Wang YI, Zeng Y, Sun HP, Qiu L, Su YI.

Mol Clin Oncol. 2015 Nov;3(6):1233-1238.

15.

Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.

Chiereghin A, Bertuzzi C, Piccirilli G, Gabrielli L, Squarzoni D, Turello G, Ferioli M, Sessa M, Bonifazi F, Zanoni L, Sabattini E, Lazzarotto T.

Transpl Immunol. 2016 Feb;34:60-4. doi: 10.1016/j.trim.2015.12.002.

PMID:
26687013
16.

EBV Status and Thiopurine Use in Pediatric IBD.

Gordon J, Ramaswami A, Beuttler M, Jossen J, Pittman N, Lai J, Dunkin D, Benkov K, Dubinsky M.

J Pediatr Gastroenterol Nutr. 2016 May;62(5):711-4. doi: 10.1097/MPG.0000000000001077.

PMID:
26655944
17.

Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.

Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N.

Clin Transplant. 2016 Jan;30(1):60-5. doi: 10.1111/ctr.12659.

PMID:
26497471
18.

Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.

Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS.

Oncotarget. 2015 Oct 20;6(32):33849-66. doi: 10.18632/oncotarget.5292.

19.

Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells.

Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, Amrolia P, Veys P.

Blood. 2015 Dec 24;126(26):2882-91. doi: 10.1182/blood-2015-06-654780.

20.

Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report.

Bennett WM, Batiuk TD, McEvoy KM, Douzdjian V, Hyde J, Shaut C, Segal GM.

Transplant Proc. 2015 Sep;47(7):2301-3. doi: 10.1016/j.transproceed.2015.07.005.

PMID:
26361705
Items per page

Supplemental Content

Loading ...
Support Center